$KPRX Today, we reported our 2025 results and business update. We begin 2026 with two Phase 2 retinal disease clinical trials underway, we're actively recruiting and dosing patients — and have a cash runway into late 2027, beyond anticipated topline data readouts. Read the full

$KPRX - We welcome Dr. Taiji Sakamoto—Chair of Ophthalmology at Kagoshima University and a leading retina specialist—to our SAB. We look forward to his guidance as we develop KIO-104 as a non-steroidal treatment option for retinal inflammation. “As we deepen our understanding of

Progress in #RetinalDisease research is advancing across four Théa programs—including our joint work on KIO-301—bring us closer to therapies with real impact. Science drives us. People inspire us. Collaboration moves us forward. https://t.co/711tQFf9Yk #kiorapharmaceuticals

Kiora is proud to join @GlobalGenes' RARE-X Vision Consortium as a founding member—collaborating to advance research and develop new therapies for rare ocular diseases. Learn more here: https://t.co/CcapdukxC3 #KioraPharmaceuticals #RAREX #GlobalGenes #VisionResearch

$KPRX Today, we announced 3rd quarter results along with an update on the progress of our development pipeline. Most importantly, patient recruitment and dosing is underway and ongoing in two active Phase 2 clinical trials: - KLARITY, evaluating KIO-104 for retinal inflammation;

We're honored to join @GlobalGenes' RARE-X Vision Consortium. Working together, advocacy groups, drug developers and researchers will be able to accelerate development of new treatments for rare eye diseases. #RareDisease #Ophthalmology

$KPRX Today we were issued a US patent on KIO-104, which extends its protection in treating ocular inflammation, uveitis, AMD, and post-surgical complications and extends exclusivity to 2043. https://t.co/TntcM17kRK

$KPRX Inherited retinal diseases need global solutions. We've partnered with Senju, a leading ophthalmic co, to advance our molecular photoswitch, KIO-301, in Asia. Deal includes $1.25M upfront option fee, up to $110M in milestones + royalties. 🔗 https://t.co/kjaAXaNAMP

$KPRX This morning, we reported Q1 results. At a high level, we continued to prepare for two Phase 2 retinal disease clinical trials and have a projected cash runway that we've extended into late 2027. Click through to read our full announcement - https://t.co/GYfgcHl2Nj

$KPRX - At ARVO 2025, we announced preclinical results demonstrating KIO-104 significantly reduced scar formation in an in vivo model of PVR. The findings further support KIO-104 as a promising candidate for inflammatory and proliferative retinal diseases. https://t.co/t1U49YR4yF

$KPRX - Our 2024 results are out. Highlights: 2 Ph 2 retinal disease trials using innovative small molecules on the brink of FPI; partnership w/Thea around KIO-301 allows us to advance both programs to readouts in 2026; cash projected into 2027. https://t.co/fVRWUBj07e

$KPRX We've secured a patent on a specific crystalline form of our KIO-104 compound targeting retinal inflammation. We expect this will extend protection of KIO-104 into 2043. Our Ph 2 trial for KIO-104 was approved earlier this week. Read more here - https://t.co/5elmFrlD3f

$KPRX - KLARITY Ph 2 Study approved to test  KIO-104 in macular edema associated w/diabetic retinopathy, non-infectious uveitis, retinal vein occlusion, or post-pseudophakic cataract surgery in up to 28 patients. Read full announcement - https://t.co/q4XYp5Q7AP

$KPRX In our Q3 results, we provided an update on our development pipeline comprised of two drug candidates entering Phase 2 trials. Balance sheet continues to provide runway beyond anticipated readouts for both studies. We invite you to read more > https://t.co/sgCDEApeg6

$KPRX Today we announced approval to begin the Phase 2 ABACUS-2 trial of KIO-301 for retinitis pigmentosa. KIO-301 is a gene mutation-agnostic small molecule that acs like a photoswitch to confer light-sensing capabilities in the presence of light.

Join Maxim's virtual Ocular Drug Development panel today at 11:00 am ET. Their research analysts sit down with executives from $BLTE, $LCTX, $OCGN & $KPRX to discuss the latest innovations in development for eye disease. Register here: https://t.co/RTomY7tYRC.

$KPRX Tue, Oct 1 @ 10:15 EDT, our CFO Melissa Tosca will participate in the @LythamIR Fall 2024 investor conference. We invite you to listen to a brief presentation followed by a fireside chat on the progress we're making against retinal disease. https://t.co/x7QcYaFCs9

Join us for a focused breakfast symposium dedicated to the exchange of info & insights on Inherited Retinal Diseases (IRDs). Seating is limited & registrations accepted on a first come, first served basis at https://t.co/zbit65RQqO #IRD #VisionAustralia #KioraPharmaceuticals

$KPRX We along with @Nasdaq want to acknowledge the incredible leadership and contributions from our Chief Financial Officer, Melissa Tosca. The recent move to CFO follows the many successes in the capital markets, strategic planning, and building out the invaluable finance team.